OxDX: Machine learning enhanced point of care diagnosis platform for infectious diseases: faster, more accessible, user intuitive, leveraging novel fluorescent labelling of enveloped viruses.

UK-based start-up OxDX Ltd will transform existing approaches to human virus detection, through the development of an infectious disease diagnosis platform, leveraging OxDX's unique pathogen identification technology.

Infectious diseases caused by pathogens like influenza, parainfluenza and respiratory syncytial virus cause many thousands of deaths annually. Current testing workflows rely heavily on centralised laboratories, with testing capacity and logistics networks struggling during peak demand spikes.

Current diagnostic approaches for virus detection, such as virus culture, RT-PCR or antigen-based rapid diagnostic tests, are often hampered by long waiting times or limited sensitivity and specificity. As a result, there is an urgent need for decentralising testing solutions, moving testing away from laboratories to the point of care that provides straightforward, fast and sensitive viral detection methods.

This project focuses on the development of OxDX's diagnostic platform, providing a step-change in cost reduction and delivering laboratory quality results at the point of care.

Suitable for utilisation by non-clinical experts beyond clinical settings, the platform can be rapidly deployed, improving global accessibility to ultra-fast, accurate infectious disease diagnostics.